You don't need to be signed in to read BMJ Group Blogs, but you can register here to receive updates about other BMJ Group products and services via our Group site.


Antiepileptic Alert: scaremongering or suicide prevention?

8 Jan, 09 | by Steven Reid, Evidence-Based Mental Health

The debate has been rumbling on for a year, but last month the US Food and Drug Administration (FDA) announced that manufacturers of antiepileptic drugs will have to add warnings to package inserts stating that these drugs increase the risk of suicide. They have also issued a public health advisory requiring that “health care professionals should notify patients, their families and caregivers of the potential for an increase in the risk of suicidal thoughts or behaviors so that patients may be closely observed”. These alerts arrive following a review of 199 clinical trials that showed a doubling of risk of suicidality (not completed suicide) in people using antiepileptics. So warning patients makes sense doesn’t it? But then why are so many neurologists, psychiatrists and notably the American Epilepsy Society unhappy with the decision?

It boils down to the perception of risk and the old relative vs. absolute question. The trials included over 40000 patients and found that the absolute risk of suicidal thinking or behavior was 0.43% in the group taking antiepileptics versus 0.24% in the group on placebo. That equates to one additional case of suicidality (again, not completed suicide) for every 500 patients taking the active drug. Do antiepileptics seem quite so scary now?

The FDA says that the warnings are needed to promote monitoring for a significant, even if small, risk. Given that epilepsy itself is associated with a threefold increased risk of completed suicide watching for signs of depression should be routine. As well as epilepsy antiepileptics are also used in bipolar disorder and with chronic pain – conditions with their own significant risk of suicide. But a regulator urging increased monitoring doesn’t seem to affect clinical practice. Take the case of antidepressant prescribing in adolescents (see an earlier post). When trials indicated an increased risk of suicidality with SSRIs the FDA slapped on a black box warning. The adolescent suicide rate went up (possibly coincidental) and prescribing rates plummeted (probably not coincidental). That’s the concern with this latest alert: people will be put off taking antiepileptic drugs, and unlike antidepressants there is no alternative treatment. Providing information is important but so is context and I think this is a decidedly dubious decision by the FDA.

EBMH blog homepage


A quarterly digest of the most important clinical research of relevance to clinicians in mental health.Visit site

Latest from Evidence-Based Mental Health

Latest from Evidence Based Mental Health